Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Metabolism and Disposition of Resveratrol in Rats: Extent of Absorption, Glucuronidation, and Enterohepatic Recirculation Evidenced by a Linked-Rat Model

Metabolism and Disposition of Resveratrol in Rats: Extent of Absorption, Glucuronidation, and... Abstract Pharmacokinetics of trans-resveratrol in its aglycone (RESAGL) and glucuronide (RESGLU) forms were studied following intravenous (15 mg/kg i.v.) and oral (50 mg/kg p.o.) administration of trans-resveratrol in a solution of β-cyclodextrin to intact rats. In addition, the enterohepatic recirculation of RESAGL and RESGLU was assessed in a linked-rat model. Multiple plasma and urine samples were collected and concentrations of RESAGL and RESGLU were determined using an electrospray ionization-liquid chromatography/tandem mass spectrometry method. After i.v. administration, plasma concentrations of RESAGL declined with a rapid elimination half-life (T1/2, 0.13 h), followed by sudden increases in plasma concentrations 4 to 8 h after drug administration. These plasma concentrations resulted in a significant prolongation of the terminal elimination half-life of RESAGL(T1/2TER, 1.31 h). RESAGLand RESGLU also displayed sudden increases in plasma concentrations 4 to 8 h after oral administration, withT1/2TER of 1.48 and 1.58 h, respectively. RESAGL bioavailability was 38% and its exposure was approximately 46-fold lower than that of RESGLU (AUCinf, 7.1 versus 324.7 μmol·h/l). Enterohepatic recirculation was confirmed in the linked-rat model since significant plasma concentrations of RESAGL and RESGLU were observed in bile-recipient rats at 4 to 8 h. The percentages of the exposures of RESAGL and RESGLU that were due to enterohepatic recirculation were 24.7 and 24.0%, respectively. The fraction of drug excreted in the urine over a period of 12 h was negligible. These results confirm that RESAGL is bioavailable and undergoes extensive first-pass glucuronidation, and that enterohepatic recirculation contributes significantly to the exposure of RESAGL and RESGLU in rats. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Pharmacology and Experimental Therapeutics Am. Soc for Pharma & Experimental Therapeutics

Metabolism and Disposition of Resveratrol in Rats: Extent of Absorption, Glucuronidation, and Enterohepatic Recirculation Evidenced by a Linked-Rat Model

5 pages

Loading next page...
 
/lp/am-soc-for-pharma-experimental-therapeutics/metabolism-and-disposition-of-resveratrol-in-rats-extent-of-absorption-13oJsRSSWK

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Am. Soc for Pharma & Experimental Therapeutics
Copyright
The American Society for Pharmacology and Experimental Therapeutics
ISSN
0022-3565
eISSN
1521-0103
DOI
10.1124/jpet.102.033340
Publisher site
See Article on Publisher Site

Abstract

Abstract Pharmacokinetics of trans-resveratrol in its aglycone (RESAGL) and glucuronide (RESGLU) forms were studied following intravenous (15 mg/kg i.v.) and oral (50 mg/kg p.o.) administration of trans-resveratrol in a solution of β-cyclodextrin to intact rats. In addition, the enterohepatic recirculation of RESAGL and RESGLU was assessed in a linked-rat model. Multiple plasma and urine samples were collected and concentrations of RESAGL and RESGLU were determined using an electrospray ionization-liquid chromatography/tandem mass spectrometry method. After i.v. administration, plasma concentrations of RESAGL declined with a rapid elimination half-life (T1/2, 0.13 h), followed by sudden increases in plasma concentrations 4 to 8 h after drug administration. These plasma concentrations resulted in a significant prolongation of the terminal elimination half-life of RESAGL(T1/2TER, 1.31 h). RESAGLand RESGLU also displayed sudden increases in plasma concentrations 4 to 8 h after oral administration, withT1/2TER of 1.48 and 1.58 h, respectively. RESAGL bioavailability was 38% and its exposure was approximately 46-fold lower than that of RESGLU (AUCinf, 7.1 versus 324.7 μmol·h/l). Enterohepatic recirculation was confirmed in the linked-rat model since significant plasma concentrations of RESAGL and RESGLU were observed in bile-recipient rats at 4 to 8 h. The percentages of the exposures of RESAGL and RESGLU that were due to enterohepatic recirculation were 24.7 and 24.0%, respectively. The fraction of drug excreted in the urine over a period of 12 h was negligible. These results confirm that RESAGL is bioavailable and undergoes extensive first-pass glucuronidation, and that enterohepatic recirculation contributes significantly to the exposure of RESAGL and RESGLU in rats.

Journal

The Journal of Pharmacology and Experimental TherapeuticsAm. Soc for Pharma & Experimental Therapeutics

Published: Jul 1, 2002

References